Journal ArticleDOI
Capecitabine as Adjuvant Treatment for Stage III Colon Cancer
Chris Twelves,A. Wong,M. Nowacki,Markus Abt,Howard A. Burris,Alfredo Carrato,Jim Cassidy,Andrés Cervantes,Jan Fagerberg,Vassilis Georgoulias,Fares Husseini,Duncan I. Jodrell,P. Koralewski,Hendrik Kröning,Jean A. Maroun,Norbert Marschner,Joseph McKendrick,M. Pawlicki,Riccardo Rosso,Johannes Schüller,Jean-François Seitz,Borut Stabuc,Jerzy Tujakowski,Guy van Hazel,Jerzy Zaluski,Werner Scheithauer +25 more
TLDR
Oral capecitabine is an effective alternative to intravenous fluorouracil plus leucovorin in the adjuvant treatment of colon cancer.Abstract:
BACKGROUND Intravenous bolus fluorouracil plus leucovorin is the standard adjuvant treatment for colon cancer. The oral fluoropyrimidine capecitabine is an established alternative to bolus fluorouracil plus leucovorin as first-line treatment for metastatic colorectal cancer. We evaluated capecitabine in the adjuvant setting. METHODS We randomly assigned a total of 1987 patients with resected stage III colon cancer to receive either oral capecitabine (1004 patients) or bolus fluorouracil plus leucovorin (Mayo Clinic regimen; 983 patients) over a period of 24 weeks. The primary efficacy end point was at least equivalence in disease-free survival; the primary safety end point was the incidence of grade 3 or 4 toxic effects due to fluoropyrimidines. RESULTS Disease-free survival in the capecitabine group was at least equivalent to that in the fluorouracil-plus-leucovorin group (in the intention-to-treat analysis, P<0.001 for the comparison of the upper limit of the hazard ratio with the noninferiority margin of 1.20). Capecitabine improved relapse-free survival (hazard ratio, 0.86; 95 percent confidence interval, 0.74 to 0.99; P=0.04) and was associated with significantly fewer adverse events than fluorouracil plus leucovorin (P<0.001). CONCLUSIONS Oral capecitabine is an effective alternative to intravenous fluorouracil plus leucovorin in the adjuvant treatment of colon cancer.read more
Citations
More filters
Journal ArticleDOI
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
TL;DR: Capecitabine and oxaliplatin are as effective as fluorouracil and cisplatin, respectively, in patients with previously untreated esophagogastric cancer, in a two-by-two design.
Journal ArticleDOI
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer
Toshiaki Watanabe,Michio Itabashi,Yasuhiro Shimada,Shinji Tanaka,Yoshinori Ito,Yoichi Ajioka,Tetsuya Hamaguchi,Ichinosuke Hyodo,Masahiro Igarashi,Hideyuki Ishida,Megumi Ishiguro,Yukihide Kanemitsu,Norihiro Kokudo,Kei Muro,Atsushi Ochiai,Masahiko Oguchi,Yasuo Ohkura,Yutaka Saito,Yoshiharu Sakai,Hideki Ueno,Takayuki Yoshino,Takahiro Fujimori,Nobuo Koinuma,Takayuki Morita,Genichi Nishimura,Yuh Sakata,Keiichi Takahashi,Hiroya Takiuchi,Osamu Tsuruta,Toshiharu Yamaguchi,Masahiro Yoshida,Naohiko Yamaguchi,Kenjiro Kotake,Kenichi Sugihara,Rectum +34 more
TL;DR: The English version of the JSCCR Guidelines 2016 is presented, which can be used as a tool for treating colorectal cancer in actual clinical practice settings and as a guide to obtaining informed consent from patients and choosing the method of treatment for each patient.
Journal ArticleDOI
Clinical practice guidelines in oncology
William J. Gradishar,Benjamin O. Anderson,Ron Balassanian,Sarah L. Blair,Harold J. Burstein,Amy E. Cyr,Anthony D. Elias,William B. Farrar,Andres Forero,Sharon H. Giordano,Matthew P. Goetz,Lori J. Goldstein,Steven J. Isakoff,Janice A. Lyons,P. Kelly Marcom,Ingrid A. Mayer,Beryl McCormick,Meena S. Moran,Ruth O'Regan,Sameer A. Patel,Lori J. Pierce,Elizabeth C. Reed,Kilian E. Salerno,Lee S. Schwartzberg,Amy Sitapati,Karen L. Smith,Mary Lou Smith,Hatem Soliman,George Somlo,Melinda L. Telli,John H. Ward,Rashmi Kumar,Dorothy A. Shead +32 more
TL;DR: This manuscript focuses on the NCCN Guidelines Panel recommendations for the workup, primary treatment, risk reduction strategies, and surveillance specific to DCIS.
Journal ArticleDOI
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
H.-J. Schmoll,E. Van Cutsem,Alexander Stein,Vincenzo Valentini,Bengt Glimelius,Bengt Glimelius,Karin Haustermans,Bernard Nordlinger,C.J.H. van de Velde,Judith Balmaña,Jaroslaw Regula,Iris D. Nagtegaal,Regina G. H. Beets-Tan,D Arnold,Fortunato Ciardiello,Paulo M. Hoff,David J. Kerr,C.-H. Köhne,Roberto Labianca,Timothy J. Price,Werner Scheithauer,Alberto Sobrero,Josep Tabernero,Dan Aderka,S Barroso,György Bodoky,J.-Y. Douillard,H El Ghazaly,Jorge Gallardo,August Garin,Rob Glynne-Jones,Karin Jordan,A Meshcheryakov,D Papamichail,Per Pfeiffer,Ioannis Souglakos,Serdar Turhal,Andrés Cervantes +37 more
TL;DR: This ESMO guideline is recommended to be used as the basis for treatment and management decisions, delivering a clear proposal for diagnostic and treatment measures in each stage of rectal and colon cancer and the individual clinical situations.
Journal ArticleDOI
Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.
Richard Gray,Jennifer Barnwell,Christopher C. McConkey,Robert Kerrin Hills,N. S. Williams,David J. Kerr +5 more
TL;DR: Chemotherapy with fluorouracil and folinic acid could improve survival of patients with stage II colorectal cancer, although the absolute improvements are small: assuming 5-year mortality without chemotherapy is 20%, the relative risk of death seen here translates into an absolute improvement in survival of 3.6%.
References
More filters
Journal ArticleDOI
Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
Thierry André,Corrado Boni,Lamia Mounedji-Boudiaf,Matilde Navarro,Josep Tabernero,Tamas Hickish,C. Topham,Marta Zaninelli,Phillip Clingan,John Bridgewater,Isabelle Tabah-Fisch,Aimery de Gramont +11 more
TL;DR: Adding oxaliplatin to a regimen of fluorouracil and leucovorin improves the adjuvant treatment of colon cancer.
Journal ArticleDOI
American Society of Clinical Oncology Recommendations on Adjuvant Chemotherapy for Stage II Colon Cancer
Al B. Benson,Deborah Schrag,Mark R. Somerfield,Alfred M. Cohen,Alvaro Figueredo,Patrick J. Flynn,Monika K. Krzyzanowska,Jean A. Maroun,Pamela K. McAllister,Eric Van Cutsem,Melissa C. Brouwers,Manya Charette,Daniel G. Haller +12 more
TL;DR: Direct evidence from randomized controlled trials does not support the routine use of adjuvant chemotherapy for patients with stage II colon cancer, and patients and oncologists who accept the relative benefit in stage III disease as adequate indirect evidence of benefit for stage II disease are justified in considering the use ofAdjuvant chemotherapy.
Journal ArticleDOI
Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue
Masanori Miwa,Masako Ura,Miwa Nishida,Noriaki Sawada,Tohru Ishikawa,Kazushige Mori,Nobuo Shimma,I. Umeda,Hideo Ishitsuka +8 more
TL;DR: Capecitabine, which is finally converted to 5-FU by dThdPase in tumours, should be much safer and more effective than5-FU, and this was indeed the case in the HCT116 human colon cancer and the MX-1 breast cancer xenograft models.
Journal ArticleDOI
Annual Report to the Nation on the status of cancer, 1973–1999, featuring implications of age and aging on U.S. cancer burden
Brenda K. Edwards,Holly L. Howe,Lynn A. G. Ries,Michael J. Thun,Harry M. Rosenberg,Rosemary Yancik,Phyllis A. Wingo,Ahmedin Jemal,Ellen G. Feigal +8 more
TL;DR: This year's report contained a special feature focusing on implications of age and aging on the U.S. cancer burden.